Stability Shapes the Future: UthPeak® NMNH Patented Crystal Forms Redefine Industry Standards

As research around NAD⁺, a key target in healthy aging, continues to advance, Reduced Nicotinamide Mononucleotide (NMNH), also known as reduced NMN, has gained global attention as a next-generation NAD⁺ precursor. Its strong biological activity and efficient conversion into NAD⁺ have positioned NMNH as a promising new direction for the industry.

However, NMNH has faced a long-standing challenge. The compound is naturally unstable and highly sensitive to moisture, making it prone to degradation. These limitations have made it challenging to transform the NMNH’s laboratory breakthrough into stable, high-quality consumer products. For years, this “stability challenge” has been one of the biggest barriers to NMNH commercialization.

EffePharm now announces a breakthrough. Its core invention patent, “Polymorphs of Reduced β-Nicotinamide Mononucleotide Calcium Salt and Their Preparation Methods and Uses” (Patent No. CN119320416B), has been officially granted by the China National Intellectual Property Administration. This innovation establishes a stable crystalline structure for NMNH, allowing the ingredient to remain stable under normal temperature and humidity conditions.

This milestone represents not only a major leap forward for EffePharm in the field of anti-aging ingredients, but also a powerful statement of its commitment to hard-core innovation, redefining the NAD⁺ anti-aging era and paving the way for the standardization, scale-up, and commercialization of NMNH.

01

Core Breakthrough:

A Comprehensive Innovation from Molecular Design to Crystal Engineering

One of the biggest obstacles in NMNH development has always been its instability. To solve this, the EffePharm R&D team moved beyond conventional approaches and focused on innovation at the molecular level. Their work resulted in the discovery of a new NMNH crystal structure with significantly improved stability.

Through systematic research, the team identified five distinct NMNH polymorphs, Forms A, B, C, D, and E, and developed precise methods to produce each one in a controlled manner. These polymorphs are not simple physical variations. Instead, each form provides structural protection that helps NMNH maintain its integrity over time.

Every polymorph has a unique and highly ordered crystal structure, creating a clear “molecular fingerprint.” These fingerprints can be identified using X-ray powder diffraction (XRPD), as shown in Figure 1. This level of control ensures consistent quality, reliable performance, and full traceability, forming a solid foundation for long-term storage and practical use.

Figure 1: Characteristic XRPD patterns of NMNH polymorphs A–E, serving as scientific proof of their unique identities and exceptional purity.

02

Disruptive Advantages:

Redefining Raw Material Standards Through “Absolute Stability”

The true value of this patent lies in its practical impact. EffePharm’s NMNH crystal technology delivers a major improvement in long-term stability and moisture resistance—two of the most critical requirements for industrial-scale application.

By significantly improving stability, this technology helps preserve NMNH activity throughout production, storage, and use. As a result, it sets a new benchmark for what high-quality NMNH raw materials should achieve.

03

From Stable Raw Materials to Reliable Clinical Outcomes:

Empowering the Entire Value Chain

Stable raw materials are the cornerstone of all applied research. Built upon this foundation, UthPeak® NMNH completed the world’s first large-scale human clinical trial of NMNH, achieving the landmark result of a “5-year reduction in biological age within 90 days.”

Phase I Clinical Validation of Safety:

The trial fully demonstrated NMNH’s excellent safety and tolerability, removing key barriers to long-term use.

Outlook for Phase II Clinical Studies:

With a stable and consistent raw material supply, EffePharm is now working with partners to advance Phase II clinical studies. These future trials aim to include larger populations and explore NMNH’s potential benefits in areas such as neuroprotection and metabolic health. When stability is secured at the source, clinical data becomes more reliable, and product development gains a clearer path forward.

04

Application Blueprint:

Opening a New Era of Diversified, High-Performance Products

With its outstanding stability and bioavailability, UthPeak® NMNH polymorph technology provides reliable support for innovation across multiple application fields. Beyond high-end NAD⁺ supplement development for anti-aging and metabolic health, it also drives continuous innovation in downstream dosage forms.

Thanks to its superior stability, NMNH can be widely applied in tablets, effervescent tablets, orally disintegrating tablets, powders, and other specialized solid formulations—unlocking broader application potential for the NAD⁺ market.

This patented technology is accelerating the evolution of NAD⁺ supplementation from “conceptual inclusion” toward an era defined by evidence-based validation, diversified dosage forms, and quantifiable outcomes, bringing transformative opportunities to the global healthy aging and wellness industry.

Conclusion

Rooted in China, Serving the World

EffePharm is not only a raw material supplier. Through foundational innovation, it aims to provide partners with solutions designed for long-term competitiveness. The approval of this NMNH polymorph patent represents a complete technological framework, combining molecular innovation, intellectual property strength, and clinical value, to support the future of NAD⁺ science on a global scale.